Comparative Pharmacology
Head-to-head clinical analysis: ATZUMI versus DIASTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATZUMI versus DIASTAT.
ATZUMI vs DIASTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
1.2 g intravenously every 12 hours over 10-12 hours.
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function (CrCl >90 mL/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in CrCl 30-50 mL/min).
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
Category C
Category C
Benzodiazepine Anticonvulsant
Benzodiazepine Anticonvulsant